Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: Comparison of dosing regimens

Archives of Dermatology

Volumn 138, Issue 9, 2002, Pages 1165-1171

  Shumack, Stephen ^a   Robinson, June ^a   Kossard, Steven ^a   Golitz, Loren ^a   Greenway, Hubert ^a   Schroeter, Arnold ^a   Andres, Kara ^a   Amies, Mark ^a   Owens, Mary ^a  

^a St George Dermatol/Skin Cancer C   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; IMMUNOMODULATING AGENT; PLACEBO;

ADULT; AGED; ARTICLE; AUSTRALIA; BASAL CELL CARCINOMA; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHEMA; EXCISION; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEW ZEALAND; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SACCHAROMYCES; SKIN BIOPSY; TOPICAL TREATMENT; TREATMENT OUTCOME; UNITED STATES;

EID: 0036715342     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.138.9.1165     Document Type: Article

References (10)

1. Cytokine induction by the immuno-modulators imiquimod and S-27609
2. Inhibition of murine tumour growth by an interferon-inducing imidazoquinolinamine
3. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection
4. Trends in non-melanocytic skin cancer treated in Australia: The second national survey
5. Basal cell carcinoma
6. Incidence of nonmelanoma skin cancer
7. Differences in age and body site distribution of the histological subtypes of basal cell carcinoma
8. Differences in age, site distribution, and sex between nodular and superficial basal cell carcinomas indicate different types of tumors
9. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicenter 6-week dose-response trial
10. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream